In HIV-1 management, eradication of the virus from sanctuaries represents a major and challenging goal. The genital tract, gut associated lymphoid tissue, lymph nodes, central nervous system, macrophages and latently infected CD4+ T lymphocytes are typical sites where HIV-1 compartmentalizes. To circumvent this problem, a consistent number of studies have focused on improving ARVs (antiretroviral drugs) delivery into sanctuary sites and different nanotechnological approaches have been developed. Cellular HIV-1 sanctuaries (i.e. macrophages) can be reached by nanoformulation of ARVs or by activation of latently infected cells. Anatomical sanctuaries (i.e. brain or male genital tract) can be addressed by increasing the permeation of ARVs across tissue barriers, such as the blood-brain barrier or the blood-testis barrier, while ARVs concentration in lymph nodes can be enhanced by drug encapsulation in CD4-targeted nanoparticles.
Antiretroviral therapy through barriers : a prominent role for nanotechnology in HIV-1 eradication from sanctuaries / F. Corsi, L. Sorrentino, S. Mazzucchelli, M. Truffi, A. Capetti, G. Rizzardini, L. Fiandra. - In: JOURNAL OF PHARMACY AND PHARMACOLOGY. - ISSN 2328-2150. - 2016:4(2016 Jul), pp. 328-340. [10.17265/2328-2150/2016.07.007]
Antiretroviral therapy through barriers : a prominent role for nanotechnology in HIV-1 eradication from sanctuaries
F. CorsiPrimo
;L. SorrentinoSecondo
;S. Mazzucchelli;M. Truffi;A. Capetti;L. Fiandra
2016
Abstract
In HIV-1 management, eradication of the virus from sanctuaries represents a major and challenging goal. The genital tract, gut associated lymphoid tissue, lymph nodes, central nervous system, macrophages and latently infected CD4+ T lymphocytes are typical sites where HIV-1 compartmentalizes. To circumvent this problem, a consistent number of studies have focused on improving ARVs (antiretroviral drugs) delivery into sanctuary sites and different nanotechnological approaches have been developed. Cellular HIV-1 sanctuaries (i.e. macrophages) can be reached by nanoformulation of ARVs or by activation of latently infected cells. Anatomical sanctuaries (i.e. brain or male genital tract) can be addressed by increasing the permeation of ARVs across tissue barriers, such as the blood-brain barrier or the blood-testis barrier, while ARVs concentration in lymph nodes can be enhanced by drug encapsulation in CD4-targeted nanoparticles.File | Dimensione | Formato | |
---|---|---|---|
7-JPP2016021701.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
Publisher's version/PDF
Dimensione
92.69 kB
Formato
Adobe PDF
|
92.69 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.